Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

90.40USD
20 Feb 2019
Change (% chg)

-- (--)
Prev Close
$90.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,812,264
52-wk High
$96.95
52-wk Low
$58.61

Select another date:

Sat, Feb 16 2019

Photo

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday.

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion (57 billion pounds) deal to buy Celgene Corp, people familiar with the matter said on Friday.

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Feb 15 Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday.

Celgene profit beats as psoriasis drug sales surge

Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla.

UPDATE 1-Celgene profit beats as psoriasis drug sales surge

Jan 31 Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla.

Celgene posts 16 pct rise in fourth quarter revenue

Jan 31 Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a nearly 16 percent rise in fourth-quarter revenue on Thursday, driven by higher sales of its blockbuster cancer drug Revlimid and psoriasis treatment Otezla.

Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal

Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion (£1.74 billion) if either of the drugmakers walks away from their $74 billion (£58.57 billion) merger announced on Thursday, according to a regulatory filing.

Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal

Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing.

Celgene, Bristol-Myers set $2.2 bln termination fee for their mega deal

Jan 4 Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing.

BRIEF-Ribon Therapeutics Raises $65 Mln

* RIBON THERAPEUTICS - RAISED $65 MILLION IN FINANCING LED BY NOVARTIS VENTURE FUND, WITH JOHNSON & JOHNSON INNOVATION - JJDC, CELGENE, EXISTING INVESTORS

Select another date: